<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Academic/Research Unit: Immunology</title>
    <link>http://hdl.handle.net/2262/32</link>
    <description>Immunology</description>
    <pubDate>Tue, 21 May 2013 15:45:53 GMT</pubDate>
    <dc:date>2013-05-21T15:45:53Z</dc:date>
    <item>
      <title>Distinct and Overlapping Effector Functions of Expanded Human CD4, CD8α and CD4CD8α Invariant Natural Killer T Cells</title>
      <link>http://hdl.handle.net/2262/61494</link>
      <description>Title: Distinct and Overlapping Effector Functions of Expanded Human CD4, CD8α and CD4CD8α Invariant Natural Killer T Cells
Author: ATZBERGER, ANN; JACKSON, JOHN; O'REILLY, VINCENT; DOHERTY, DEREK; FEIGHERY, CONLETH FRANCIS; ZENG, SHIJUAN GRACE
Abstract: CD1d-restricted invariant natural killer T (iNKT) cells have diverse immune stimulatory/regulatory activities through their ability to release cytokines and to kill or transactivate other cells. Activation of iNKT cells can protect against multiple diseases in mice but clinical trials in humans have had limited impact. Clinical studies to date have targeted polyclonal mixtures of iNKT cells and we proposed that their subset compositions will influence therapeutic outcomes. We sorted and expanded iNKT cells from healthy donors and compared the phenotypes, cytotoxic activities and cytokine profiles of the CD4(+), CD8α(+) and CD4(-)CD8α(-) double-negative (DN) subsets. CD4(+) iNKT cells expanded more readily than CD8α(+) and DN iNKT cells upon mitogen stimulation. CD8α(+) and DN iNKT cells most frequently expressed CD56, CD161 and NKG2D and most potently killed CD1d(+) cell lines and primary leukemia cells. All iNKT subsets released Th1 (IFN-γ and TNF-α) and Th2 (IL-4, IL-5 and IL-13) cytokines. Relative amounts followed a CD8α&gt;DN&gt;CD4 pattern for Th1 and CD4&gt;DN&gt;CD8α for Th2. All iNKT subsets could simultaneously produce IFN-γ and IL-4, but single-positivity for IFN-γ or IL-4 was strikingly rare in CD4(+) and CD8α(+) fractions, respectively. Only CD4(+) iNKT cells produced IL-9 and IL-10; DN cells released IL-17; and none produced IL-22. All iNKT subsets upregulated CD40L upon glycolipid stimulation and induced IL-10 and IL-12 secretion by dendritic cells. Thus, subset composition of iNKT cells is a major determinant of function. Use of enriched CD8α(+), DN or CD4(+) iNKT cells may optimally harness the immunoregulatory properties of iNKT cells for treatment of disease.
Description: PUBLISHED</description>
      <pubDate>Sat, 01 Jan 2011 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/2262/61494</guid>
      <dc:date>2011-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.</title>
      <link>http://hdl.handle.net/2262/59036</link>
      <description>Title: Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.
Author: DOHERTY, DEREK; O'REILLY, VINCENT
Abstract: AIMS/HYPOTHESIS:&#xD;
The innate immune cells, invariant natural killer T cells (iNKT cells), are implicated in the pathogenesis of psoriasis, an inflammatory condition associated with obesity and other metabolic diseases, such as diabetes and dyslipidaemia. We observed an improvement in psoriasis severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor agonist. This was independent of change in glycaemic control. We proposed that this unexpected clinical outcome resulted from a direct effect of GLP-1 on iNKT cells.&#xD;
METHODS:&#xD;
We measured circulating and psoriatic plaque iNKT cell numbers in two patients with type 2 diabetes and psoriasis before and after commencing GLP-1 analogue therapy. In addition, we investigated the in vitro effects of GLP-1 on iNKT cells and looked for a functional GLP-1 receptor on these cells.&#xD;
RESULTS:&#xD;
The Psoriasis Area and Severity Index improved in both patients following 6 weeks of GLP-1 analogue therapy. This was associated with an alteration in iNKT cell number, with an increased number in the circulation and a decreased number in psoriatic plaques. The GLP-1 receptor was expressed on iNKT cells, and GLP-1 induced a dose-dependent inhibition of iNKT cell cytokine secretion, but not cytolytic degranulation in vitro.&#xD;
CONCLUSIONS/INTERPRETATION:&#xD;
The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.
Description: PUBLISHED</description>
      <pubDate>Sat, 01 Jan 2011 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/2262/59036</guid>
      <dc:date>2011-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Preferential Th1 Cytokine Profile of Phosphoantigen-Stimulated Human Vγ9Vδ2 T Cells</title>
      <link>http://hdl.handle.net/2262/54842</link>
      <description>Title: Preferential Th1 Cytokine Profile of Phosphoantigen-Stimulated Human Vγ9Vδ2 T Cells
Author: MANGAN, BOZEANA; DOHERTY, DEREK; DUNNE, MARGARET
Abstract: Human Vγ9Vδ2 T cells recognise pyrophosphate-based antigens (phosphoantigens) and have multiple functions in innate and adaptive immunity, including a unique ability to activate other cells of the immune system. We used flow cytometry and ELISA to define the early cytokine profiles of Vγ9Vδ2 T cells stimulated in vitro with isopentenyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2 enyl pyrophosphate (HMB-PP) in the absence and presence of IL-2 and IL-15. We show that fresh Vγ9Vδ2 T cells produce interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) within 4 hours of stimulation with phosphoantigen, but neither IL-10, IL-13, nor IL-17 was detectable up to 72 hours under these conditions. Cytokine production was not influenced by expression or lack, thereof, of CD4 or CD8. Addition of IL-2 or IL-15 caused expansion of IFN-γ-producing Vγ9Vδ2 T cells, but did not enhance IFN-γ secretion after 24-72 hours. Thus, phosphoantigen-stimulated Vγ9Vδ2 T cells have potential as Th1-biasing adjuvants for immunotherapy.
Description: PUBLISHED</description>
      <pubDate>Fri, 01 Jan 2010 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/2262/54842</guid>
      <dc:date>2010-01-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

